Literature DB >> 34894127

Prevalence of Discordant Procalcitonin Use at an Academic Medical Center.

Gregory B Seymann1, Nicholas Bevins2, Christina Wu3,4, Robert Fitzgerald2.   

Abstract

OBJECTIVES: Despite multiple trials demonstrating that procalcitonin (PCT) is an effective tool for antibiotic stewardship, inconsistent application in real-world settings continues to fuel controversy regarding its clinical utility. We sought to determine rates of concordance between PCT results and antibiotic prescribing in hospitalized patients.
METHODS: We performed a retrospective review of all inpatient encounters at an academic tertiary care health system with a PCT result between February 2017 and October 2019. Concordant prescribing was defined as starting or continuing antibiotics following an elevated PCT (>0.5 ng/mL) finding and withholding or stopping antibiotics following a low PCT (< 0.1 ng/mL) finding.
RESULTS: Antibiotic prescribing decisions were discordant from the PCT level in 32.5% of our sample. Among patients not receiving antibiotics at the time of testing, 25.9% (430 of 1,662) were prescribed antibiotics despite a low PCT result. Among patients already receiving antibiotics, treatment was continued despite a low PCT level in 80.4% (728 of 906) of cases. Enhanced decision support tools introduced during the study period had no impact on PCT use for antibiotic decisions.
CONCLUSIONS: Overall concordance between PCT results and antibiotic use is relatively low in a real-world setting. The potential value of PCT for antibiotic stewardship may not be fully realized.
© The Author(s) 2021. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antibiotic stewardship; High-value care; Procalcitonin

Mesh:

Substances:

Year:  2022        PMID: 34894127      PMCID: PMC9171572          DOI: 10.1093/ajcp/aqab201

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   5.400


  8 in total

1.  Unnecessary use of antimicrobials in hospitalized patients: current patterns of misuse with an emphasis on the antianaerobic spectrum of activity.

Authors:  Michelle T Hecker; David C Aron; Nilam P Patel; Meghan K Lehmann; Curtis J Donskey
Journal:  Arch Intern Med       Date:  2003-04-28

2.  Annals Clinical Decision Making: Using a Diagnostic Test.

Authors:  Katrina A Armstrong; Joshua P Metlay
Journal:  Ann Intern Med       Date:  2020-04-21       Impact factor: 25.391

3.  Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis.

Authors:  Philipp Schuetz; Yannick Wirz; Ramon Sager; Mirjam Christ-Crain; Daiana Stolz; Michael Tamm; Lila Bouadma; Charles E Luyt; Michel Wolff; Jean Chastre; Florence Tubach; Kristina B Kristoffersen; Olaf Burkhardt; Tobias Welte; Stefan Schroeder; Vandack Nobre; Long Wei; Heiner C Bucher; Djillali Annane; Konrad Reinhart; Ann R Falsey; Angela Branche; Pierre Damas; Maarten Nijsten; Dylan W de Lange; Rodrigo O Deliberato; Carolina F Oliveira; Vera Maravić-Stojković; Alessia Verduri; Bianca Beghé; Bin Cao; Yahya Shehabi; Jens-Ulrik S Jensen; Caspar Corti; Jos A H van Oers; Albertus Beishuizen; Armand R J Girbes; Evelien de Jong; Matthias Briel; Beat Mueller
Journal:  Lancet Infect Dis       Date:  2017-10-13       Impact factor: 25.071

4.  Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis.

Authors:  Stephanie Royer; Kimberley M DeMerle; Robert P Dickson; Hallie C Prescott
Journal:  J Hosp Med       Date:  2018-01-25       Impact factor: 2.960

5.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial.

Authors:  Lila Bouadma; Charles-Edouard Luyt; Florence Tubach; Christophe Cracco; Antonio Alvarez; Carole Schwebel; Frédérique Schortgen; Sigismond Lasocki; Benoît Veber; Monique Dehoux; Maguy Bernard; Blandine Pasquet; Bernard Régnier; Christian Brun-Buisson; Jean Chastre; Michel Wolff
Journal:  Lancet       Date:  2010-01-25       Impact factor: 79.321

6.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

Authors:  Evelien de Jong; Jos A van Oers; Albertus Beishuizen; Piet Vos; Wytze J Vermeijden; Lenneke E Haas; Bert G Loef; Tom Dormans; Gertrude C van Melsen; Yvette C Kluiters; Hans Kemperman; Maarten J van den Elsen; Jeroen A Schouten; Jörn O Streefkerk; Hans G Krabbe; Hans Kieft; Georg H Kluge; Veerle C van Dam; Joost van Pelt; Laura Bormans; Martine Bokelman Otten; Auke C Reidinga; Henrik Endeman; Jos W Twisk; Ewoudt M W van de Garde; Anne Marie G A de Smet; Jozef Kesecioglu; Armand R Girbes; Maarten W Nijsten; Dylan W de Lange
Journal:  Lancet Infect Dis       Date:  2016-03-02       Impact factor: 25.071

7.  Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence.

Authors:  Michael R Broyles
Journal:  Open Forum Infect Dis       Date:  2017-10-03       Impact factor: 3.835

8.  Assessment of the Appropriateness of Antimicrobial Use in US Hospitals.

Authors:  Shelley S Magill; Erin O'Leary; Susan M Ray; Marion A Kainer; Christopher Evans; Wendy M Bamberg; Helen Johnston; Sarah J Janelle; Tolulope Oyewumi; Ruth Lynfield; Jean Rainbow; Linn Warnke; Joelle Nadle; Deborah L Thompson; Shamima Sharmin; Rebecca Pierce; Alexia Y Zhang; Valerie Ocampo; Meghan Maloney; Samantha Greissman; Lucy E Wilson; Ghinwa Dumyati; Jonathan R Edwards; Nora Chea; Melinda M Neuhauser
Journal:  JAMA Netw Open       Date:  2021-03-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.